6. Revolution Medicines Inc. (NASDAQ:RVMD)
Stock Upside Potential: 26.47%
Year-to-Date Gain: 71.22%
Revolution Medicines, Inc. is one of the highest-upside biotech stocks in the current market, driven by strong clinical progress and analyst upgrades.
On April 23, Mizuho reiterated an outperform rating and raised its price target to $185 from $140, reflecting increased confidence in the company’s lead drug candidate, daraxonrasib, for pancreatic cancer treatment.
The firm raised the probability of success for the drug to 90% from 80%, supported by recent clinical trial data. Early first-line treatment data showed results comparable to existing therapies, while second-line treatment performance continues to support further development.
Mizuho also expects daraxonrasib to generate up to $14 billion in risk-adjusted revenue by 2035, positioning it as a major potential breakthrough in oncology.
On April 27, the company also accused Erasca of patent infringement related to its cancer drug program. While the dispute created short-term volatility, it does not change the long-term outlook driven by clinical progress.
Revolution Medicines focuses on RAS-driven cancers, which account for roughly 30% of human cancers. Its proprietary tri-complex inhibitor platform targets active RAS proteins, a space with limited competition and high unmet medical need.
This combination of strong pipeline potential, high probability of success, and large addressable market keeps the stock firmly positioned among the best biotech stocks to buy now.
YOU MUST READ THIS: Top 8 Cheap Stocks Under $5 That Smart Investors Are Secretly Buying
Click here to continue reading and checkout the Top 5 Stocks to Buy Now That Could Deliver 20%+ Upside Fast.
Disclosure: No material interests to disclose. This article was originally published on Global Market Bulletin.
